Positive News SentimentPositive NewsNASDAQ:NOVN Novan (NOVN) Stock Forecast, Price & News $1.19 +0.04 (+3.48%) (As of 05/30/2023 ET) Add Compare Share Share Today's Range$1.12▼$1.2050-Day Range$1.11▼$1.4052-Week Range$0.79▼$3.33Volume123,021 shsAverage Volume159,389 shsMarket Capitalization$33.33 millionP/E RatioN/ADividend YieldN/APrice Target$12.33 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media Novan MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside936.4% Upside$12.33 Price TargetShort InterestBearish1.74% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthGrowingFrom ($0.99) to ($0.54) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.83 out of 5 starsMedical Sector782nd out of 1,009 stocksPharmaceutical Preparations Industry394th out of 494 stocks 3.5 Analyst's Opinion Consensus RatingNovan has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $12.33, Novan has a forecasted upside of 936.4% from its current price of $1.19.Amount of Analyst CoverageNovan has only been the subject of 1 research reports in the past 90 days. Previous Next 2.0 Short Interest Percentage of Shares Shorted1.74% of the outstanding shares of Novan have been sold short.Short Interest Ratio / Days to CoverNovan has a short interest ratio ("days to cover") of 4.1.Change versus previous monthShort interest in Novan has recently increased by 4.45%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldNovan does not currently pay a dividend.Dividend GrowthNovan does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for NOVN. Previous Next 2.7 News and Social Media Coverage News SentimentNovan has a news sentiment score of 1.89. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.78 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Novan this week, compared to 1 article on an average week.Search InterestOnly 5 people have searched for NOVN on MarketBeat in the last 30 days. This is a decrease of -81% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Novan to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Novan insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 2.00% of the stock of Novan is held by insiders.Percentage Held by InstitutionsOnly 20.68% of the stock of Novan is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Novan are expected to grow in the coming year, from ($0.99) to ($0.54) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Novan is -0.90, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Novan is -0.90, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioNovan has a P/B Ratio of 6.26. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Novan (NASDAQ:NOVN) StockNovan, Inc. is a medical dermatology company, which engages in the development and commercialization of therapeutic products for skin diseases. It operates through the Commercial Operations and Research and Development segments. The Commercial Operations segment involves the promotion of treatments for medical dermatology conditions products. The Research and Development Operations segment includes the development of nitric oxide-based technology products. The company was founded by Mark Schoenfisch and Nathan Stasko in 2006 and is headquartered in Durham, NC.Read More Receive NOVN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Novan and its competitors with MarketBeat's FREE daily newsletter. Email Address NOVN Stock News HeadlinesMay 21, 2023 | fool.comNovan (NASDAQ: NOVN)May 21, 2023 | americanbankingnews.comStockNews.com Begins Coverage on Novan (NASDAQ:NOVN)May 30, 2023 | Behind the Markets (Ad)Why Your IRA Could Crash on June 16thChina will attack Taiwan as soon as June 16th, 2023. The stock market will crash at least 35% when China makes their move.May 17, 2023 | americanbankingnews.comNovan (NASDAQ:NOVN) Posts Earnings Results, Misses Expectations By $0.22 EPSMay 17, 2023 | msn.comOppenheimer Maintains Novan (NOVN) Outperform RecommendationMay 16, 2023 | finance.yahoo.comNOVN: Counting Down to PDUFAMay 15, 2023 | finanznachrichten.deNovan, Inc.: Novan Reports First Quarter 2023 Financial Results and Provides Corporate UpdateMay 15, 2023 | markets.businessinsider.comNovan earnings: here's what Wall Street expectsMay 30, 2023 | Behind the Markets (Ad)Why Your IRA Could Crash on June 16thChina will attack Taiwan as soon as June 16th, 2023. The stock market will crash at least 35% when China makes their move.May 14, 2023 | americanbankingnews.comNovan (NOVN) to Release Earnings on MondayMay 12, 2023 | msn.comEarnings Preview: NovanMay 12, 2023 | msn.comNovan Q1 2023 Earnings PreviewApril 20, 2023 | finance.yahoo.comNovan to Host Analyst and Investor Event: A Discussion of Molluscum’s Unmet Need with Pediatric Dermatologist Jeffrey Sugarman, MD, PhDApril 7, 2023 | americanbankingnews.comOppenheimer Research Analysts Reduce Earnings Estimates for Novan, Inc. (NASDAQ:NOVN)April 5, 2023 | americanbankingnews.comQ1 2023 Earnings Forecast for Novan, Inc. (NASDAQ:NOVN) Issued By OppenheimerApril 3, 2023 | msn.comNovan's Return On Capital Employed OverviewApril 3, 2023 | americanbankingnews.comNovan's (NOVN) "Overweight" Rating Reiterated at Cantor FitzgeraldApril 3, 2023 | americanbankingnews.comNovan (NASDAQ:NOVN) Raised to Hold at StockNews.comMarch 23, 2023 | finance.yahoo.comNovan to Report Full Year 2022 Financial Results on March 30, 2023March 21, 2023 | americanbankingnews.comAnalysts Offer Predictions for Novan, Inc.'s Q1 2023 Earnings (NASDAQ:NOVN)March 7, 2023 | finance.yahoo.comFDA Accepts Novan’s NDA for Berdazimer Gel, 10.3% for the Treatment of Molluscum Contagiosum with a PDUFA Goal Date of January 5, 2024October 19, 2022 | reuters.comJPMorgan names Qian as Southeast Asia equity capital markets chief - ReutersOctober 14, 2022 | finance.yahoo.comNovan and EPI Health, a Novan Company, Announce Abstracts Accepted for Poster Presentation at the 42nd Annual Fall Clinical Dermatology Conference® - Yahoo FinanceOctober 14, 2022 | globenewswire.comNovan and EPI Health, a Novan Company, Announce Abstracts Accepted for Poster Presentation at the 42nd Annual Fall Clinical Dermatology Conference - GlobeNewswireOctober 14, 2022 | finance.yahoo.comNovan and EPI Health, a Novan Company, Announce Abstracts Accepted for Poster Presentation at the 42nd Annual Fall Clinical Dermatology Conference®October 6, 2022 | finance.yahoo.comGlobal Acne Treatment Market (2022 Edition)– Analysis By Treatment, Treatment Modality, End-Users, By Region, By Country: Market Insights and Forecast with Impact of COVID-19 (2023-2028) - Yahoo FinanceOctober 3, 2022 | finance.yahoo.comWorldwide Acne Treatment Industry to 2027 - Focus on Retinoids, Antibiotics, Hormonal Drugs, Anti-Inflammatory Drugs and Chemical Peels - Yahoo FinanceSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive NOVN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Novan and its competitors with MarketBeat's FREE daily newsletter. Email Address NOVN Company Calendar Last Earnings3/30/2023Today5/30/2023Next Earnings (Estimated)8/10/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:NOVN CUSIPN/A CIK1467154 Webwww.novan.com Phone(919) 485-8080Fax919-237-9212Employees29Year FoundedN/APrice Target and Rating Average Stock Price Forecast$12.33 High Stock Price Forecast$17.00 Low Stock Price Forecast$8.00 Forecasted Upside/Downside+936.4%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($1.32) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-31,310,000.00 Net Margins-128.61% Pretax Margin-128.39% Return on Equity-700.28% Return on Assets-39.58% Debt Debt-to-Equity RatioN/A Current Ratio0.74 Quick Ratio0.72 Sales & Book Value Annual Sales$23.68 million Price / Sales1.41 Cash FlowN/A Price / Cash FlowN/A Book Value$0.19 per share Price / Book6.26Miscellaneous Outstanding Shares28,010,000Free Float27,455,000Market Cap$33.33 million OptionableNot Optionable Beta0.17 Key ExecutivesPaula Brown StaffordChairman, President & Chief Executive OfficerJohn A. DonofrioChief Operating Officer & Executive Vice PresidentJohn M. GaySecretary, Chief Financial & Accounting OfficerCarri GeerChief Technology Officer & Senior Vice PresidentTomoko Maeda-ChubachiChief Medical OfficerKey CompetitorsSatsuma PharmaceuticalsNASDAQ:STSAAcurx PharmaceuticalsNASDAQ:ACXPOrgenesisNASDAQ:ORGSFlora GrowthNASDAQ:FLGCYumanity TherapeuticsNASDAQ:YMTXView All CompetitorsInstitutional OwnershipB. Riley Wealth Advisors Inc.Bought 32,000 shares on 5/17/2023Ownership: 0.668%Armistice Capital LLCBought 2,247,248 shares on 5/16/2023Ownership: 8.022%Two Sigma Securities LLCBought 38,825 shares on 5/15/2023Ownership: 0.139%Renaissance Technologies LLCSold 71,300 shares on 5/12/2023Ownership: 0.305%Oak Harbor Wealth Partners LLCSold 25,200 shares on 4/24/2023Ownership: 0.097%View All Institutional Transactions NOVN Stock - Frequently Asked Questions Should I buy or sell Novan stock right now? 3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Novan in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" NOVN shares. View NOVN analyst ratings or view top-rated stocks. What is Novan's stock price forecast for 2023? 3 brokerages have issued 12-month target prices for Novan's stock. Their NOVN share price forecasts range from $8.00 to $17.00. On average, they predict the company's share price to reach $12.33 in the next year. This suggests a possible upside of 936.4% from the stock's current price. View analysts price targets for NOVN or view top-rated stocks among Wall Street analysts. How have NOVN shares performed in 2023? Novan's stock was trading at $1.46 on January 1st, 2023. Since then, NOVN shares have decreased by 18.5% and is now trading at $1.19. View the best growth stocks for 2023 here. When is Novan's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, August 10th 2023. View our NOVN earnings forecast. How were Novan's earnings last quarter? Novan, Inc. (NASDAQ:NOVN) posted its quarterly earnings data on Thursday, March, 30th. The company reported ($0.09) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.31) by $0.22. The firm earned $10.48 million during the quarter, compared to the consensus estimate of $6.07 million. Novan had a negative net margin of 128.61% and a negative trailing twelve-month return on equity of 700.28%. What other stocks do shareholders of Novan own? Based on aggregate information from My MarketBeat watchlists, some companies that other Novan investors own include Bionano Genomics (BNGO), Gran Tierra Energy (GTE), Pennsylvania Real Estate Investment Trust (PEI), ADMA Biologics (ADMA), CNBX Pharmaceuticals (CNBX), Matinas BioPharma (MTNB), Zosano Pharma (ZSAN), Aeterna Zentaris (AEZS), CBL & Associates Properties (CBL) and Organigram (OGI). When did Novan IPO? (NOVN) raised $46 million in an initial public offering (IPO) on Wednesday, September 21st 2016. The company issued 3,800,000 shares at a price of $11.00-$13.00 per share. Piper Jaffray served as the underwriter for the IPO and JMP Securities and Wedbush PacGrow were co-managers. What is Novan's stock symbol? Novan trades on the NASDAQ under the ticker symbol "NOVN." Who are Novan's major shareholders? Novan's stock is owned by many different retail and institutional investors. Top institutional investors include Armistice Capital LLC (8.02%), B. Riley Wealth Advisors Inc. (0.67%), Renaissance Technologies LLC (0.30%), Two Sigma Securities LLC (0.14%) and Oak Harbor Wealth Partners LLC (0.10%). Insiders that own company stock include James L Bierman, John M Gay, John W Palmour and Paula B Stafford. View institutional ownership trends. How do I buy shares of Novan? Shares of NOVN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Novan's stock price today? One share of NOVN stock can currently be purchased for approximately $1.19. How much money does Novan make? Novan (NASDAQ:NOVN) has a market capitalization of $33.33 million and generates $23.68 million in revenue each year. The company earns $-31,310,000.00 in net income (profit) each year or ($1.32) on an earnings per share basis. How can I contact Novan? Novan's mailing address is 4105 HOPSON ROAD, MORRISVILLE NC, 27560. The official website for the company is www.novan.com. The company can be reached via phone at (919) 485-8080, via email at cikkala@novan.com, or via fax at 919-237-9212. This page (NASDAQ:NOVN) was last updated on 5/30/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Novan, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.